References
- MacGregor RR, Graziani AL. Oral administration of antibiotics: a rational alternative to the parenteral route. Clin Infect Dis 1997; 24(3):457–67
- Craig WA, Andes DR. Parenteral versus oral antibiotic therapy. Med Clin North Am 1995; 79(3):497–508
- Bonkovsky HL. The alphabet soup of viral hepatitis: is G a new flavi(or) in the mix? (Editorial) West J Med 1997; 167(1):50–1
- Lieberman D, Kahane S, Lieberman D, et al. Pneumonia with serological evidence of acute infection with the chlamydia-like microorganism “Z.” Am J Respir Crit Care Med 1997; 156(2 Pt 1):578–82
- File TM Jr, Tan JS. Incidence, etiologic pathogens, and diagnostic testing of community-acquired pneumonia. Curr Opin Pulm Med 1997; 3(2):89–97
- Monitoring and management of bacterial resistance to antimicrobial agents: a World Health Organization symposium. Geneva, Switzerland, 29 November-2 December, 1995. Clin Infect Dis 1997; 24 (Suppl 1):S1–176
- Centers for Disease Control and Prevention. Multidrug-resistant Salmonella serotype Typhimurium—United States, 1996. MMWR Morb Mortal Wkly Rep 1997; 46(14):308–10
- Centers for Disease Control and Prevention. Staphylococcus aureus with reduced susceptibility to vancomycin—United States, 1997. MMWR Morb Mortal Wkly Rep 1997; 46(33):765–6 [Erratum, MMWR Morb Mortal Wkly Rep 1997; 46(36):851]
- Piscitelli SC, Danziger LH, Rodvold KA. Clarithromycin and azithromycin: new macrolide antibiotics. Clin Pharm 1992; 11(2):137–52 [Erratum, Clin Pharm 1992; 11(4):308]
- Borrego F, Gleckman R. Principles of antibiotic prescribing in the elderly. Drugs Aging 1997; 11(1):7–18
- Pelletier LL Jr. Review of the experience with cefprozil for the treatment of lower respiratory tract infections. Clin Infect Dis 1992; 14(Suppl 2):S238–43; discussion S244-5
- Geddes AM. Cefpodoxime proxetil in the treatment of lower respiratory tract infections. Drugs 1991; 42(Suppl 3):34–40
- Chirurgi VA, Edelstein H, Oster SE, et al. Ceftibuten versus cefaclor for the treatment of bronchitis. J Antimicrob Chemother 1991; 28(4):577–80
- Zeckel ML. Loracarbef (LY163892) in the treatment of acute exacerbations of chronic bronchitis: results of US and European comparative clinical trials. Am J Med 1992; 92(6A):58–64S
- Khan W A, Seas C, Dhar U, et al. Treatment of shigellosis. V. Comparison of azithromycin and ciprofloxacin: a double-blind, randomized, controlled trial. Ann Intern Med 1997; 126(9):697–703
- Gupta S, Leatham EW, Carrington D, et al. The effect of azithromycin in post-myocardial infarction (MI) patients with elevated Chlamydia pneumoniae antibody titres. J Am Coll Cardiol 1997; 29(Suppl A):209A
- Logan RP, Gummett PA, Schaufel-berger HD, et al. Eradication of Helicobacter pylori with clarithromycin and omeprazole. Gut 1994; 35(3):323–6
- Ortqvist A, Valtonen M, Cars O, et al, for the Scandinavian Sparfloxacin Study Group. Oral empiric treatment of community-acquired pneumonia: a multicenter, double-blind, randomized study comparing Sparfloxacin with roxithromycin. Chest 1996; 110(6):1499–506
- Goa KL, Bryson HM, Markham A. Sparfloxacin: a review of its antibacterial activity, pharmacokinetic properties, clinical efficacy and tolerability in lower respiratory tract infections. Drugs 1997; 53(4): 700–25
- Wagstaff AJ, Balfour JA. Grepafloxacin. Drugs 1997; 53(5):817–24; discussion 825–7
- Haria M, Lamb HM. Trovafloxacin. Drugs 1997; 54(3):435–45; discussion 446
- Joshi N, Milfred D. The use and misuse of new antibiotics: a perspective. Arch Intern Med 1995; 155(6):569–77